Gastric cancer remains a formidable adversary, ranking as the fifth most common cancer and the third-leading cause of cancer-related deaths worldwide, with more than 1,000,000 new cases and close to ...

Gastric cancer remains a formidable adversary, ranking as the fifth most common cancer and the third-leading cause of cancer-related deaths worldwide, with over 1,000,000 new cases and close to ...

Six studies were analyzed. Of the total 757 patients with gastric adenocarcinoma, 318 (42.0%) were stage I, 311 (41.0%) were stage II/III, 116 (15.3%) were stage IV, and 22 (2.9%) were undetermined.

Image Caption: Proteomic alterations in post-NACT OCPM tissues. Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the ...

The FDA approved relacorilant (Lifyorli) in combination with nab-paclitaxel (Abraxane) for the treatment of adults with ...

Corcept Therapeutics recently received U.S. FDA approval for Lifyorli (relacorilant) plus nab-paclitaxel to treat adults with platinum-resistant epithelial ovarian, fallopian tube, or primary ...

Researchers from National University Hospital (NUH), National Cancer Institute, Singapore (NCIS), the Yong Loo Lin School of Medicine, National University of Singapore, Duke-NUS Medical School and ...